| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/21/2000 | WO2000054751A1 Method for producing solid dosage forms containing cyclodextrin |
| 09/21/2000 | WO2000054749A1 Media in the form of complex dispersions, method for preparing same and uses |
| 09/21/2000 | WO2000054745A2 Devices and methods for pain management |
| 09/21/2000 | WO2000054741A1 USE OF NANOSCALAR WATER-SOLUBLE β-(1,3) GLUCANS |
| 09/21/2000 | WO2000054593A1 Iodine preparation compositon |
| 09/21/2000 | WO2000043043B1 Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery |
| 09/21/2000 | WO2000027207A8 Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof |
| 09/21/2000 | WO2000026185A9 Omeprazole solution and method of using same |
| 09/21/2000 | WO2000021560A9 Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY |
| 09/21/2000 | WO2000021505A3 Composition for the parenteral administration of active agents |
| 09/21/2000 | DE19918105C1 Transdermal patch for administering neuroleptic agent i.e. fluphenazine, flupentixol or triflupromazine, includes matrix layer containing penetration enhancer and hydrocarbon polymer |
| 09/21/2000 | DE19912502A1 Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung Nanoscale particles, complexes with polynucleotides and their use |
| 09/21/2000 | DE19912436A1 Ibuprofen-Lösung Ibuprofen solution |
| 09/21/2000 | DE19911329A1 Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung Human Therapeutic applicable radioimmunoconjugate and process for its preparation |
| 09/21/2000 | DE19911058A1 Verwendung von nanoskaligen wasserlöslichen beta-(1,3)-Glucanen The use of nanoscale water-soluble beta- (1,3) glucans |
| 09/21/2000 | CA2368150A1 1-acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors |
| 09/21/2000 | CA2367917A1 Bacterial membrane fractions with adjuvant effect |
| 09/21/2000 | CA2367875A1 Use of nanoscalar water-soluble .beta.-(1,3) glucans |
| 09/21/2000 | CA2367605A1 Apomorphine and sildenafil composition |
| 09/21/2000 | CA2367409A1 Metering valve |
| 09/21/2000 | CA2367357A1 Method |
| 09/21/2000 | CA2365767A1 Angiogenesis inhibition |
| 09/21/2000 | CA2363705A1 Devices and methods for pain management |
| 09/20/2000 | EP1036783A1 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt |
| 09/20/2000 | EP1036510A2 Vitamin formulation for cardiovascular health |
| 09/20/2000 | EP1036167A2 Nuclear targeting by means of streptococcal protein h |
| 09/20/2000 | EP1036093A1 Conjugates useful in the treatment of prostate cancer |
| 09/20/2000 | EP1036057A1 Radio-opaque polymer biomaterials |
| 09/20/2000 | EP1035869A1 Chemically and thermally stable norastemizole formulations |
| 09/20/2000 | EP1035867A1 Transdermal delivery of particulate vaccine compositions |
| 09/20/2000 | EP1035859A1 THE USE OF PHOSPHOLIPID COMPLEXES OF EXTRACTS OF $i(VITIS VINIFERA) AS ANTI-ATHEROSCLEROTIC AGENTS |
| 09/20/2000 | EP1035847A1 Stable solution of zinc and bicarbonate ions |
| 09/20/2000 | EP1035841A1 Method for producing solid dosing forms |
| 09/20/2000 | EP1035840A1 Sustained release formulation containing three different types of polymers and tablet formed therefrom |
| 09/20/2000 | EP1035837A2 Lipid compositions and their use |
| 09/20/2000 | EP1035836A1 Improved method for avoiding the degradation of an active principle |
| 09/20/2000 | EP1035835A1 Long acting injectable formulations containing hydrogenated castor oil |
| 09/20/2000 | EP1035833A1 Compositions for nasal administration |
| 09/20/2000 | EP1011705A4 Conjugates targeted to the interleukin-2 receptor |
| 09/20/2000 | EP0504327B1 Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof |
| 09/20/2000 | CN1267221A Method of enhancing bioavailability of fexofenadine and its derivs. |
| 09/20/2000 | CN1267216A In situ formation of polymeric material |
| 09/20/2000 | CN1267215A Pharmacetical compositions contg. effervescent acid-base couple |
| 09/20/2000 | CN1267191A Composition and method for treating penile erectile dysfunction |
| 09/20/2000 | CN1266679A Nanoemulsion based on ethoxylated fatly ether or ethoxylated fatty ester, and use thereof |
| 09/19/2000 | US6121433 For diagnostic, research and therapeutic use; mimic or modulate proteins, enzymes, nucleic acids and lipids |
| 09/19/2000 | US6121426 Fibrin binding domain polypeptides and uses and methods of producing same |
| 09/19/2000 | US6121425 Metal-lipid molecules |
| 09/19/2000 | US6121375 Gels formed by the interaction of poly(aldehyde) with various substances |
| 09/19/2000 | US6121314 Pharmaceutical composition |
| 09/19/2000 | US6121313 Pharmaceutical composition in a form of self-emulsifying formulation for lipophilic compounds |
| 09/19/2000 | US6121302 Broad spectrum preservative comprising isothiazolones with alkanol-substituted dimethylhydantoin as formaldehyde donor, and an alkyl hydantoin as a stabilizer for isothiazolone; low free formaldehyde, stable in large ph range |
| 09/19/2000 | US6121253 Prostaglandin conjugates for treating or preventing bone disease |
| 09/19/2000 | US6121242 Treatment of bacterial dysentery |
| 09/19/2000 | US6121234 Use of essential oils to increase bioavailability of orally administered pharmaceutical compounds |
| 09/19/2000 | US6121233 Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules |
| 09/19/2000 | US6120807 Prolonged release of GM-CSF |
| 09/19/2000 | US6120804 Topical drug preparations |
| 09/19/2000 | US6120803 Having segment of dosage form that is of sufficient rigidity to withstand contractions of stomach and delay expulsion of dosage form from stomach until substantially all of active agent has been dispensed |
| 09/19/2000 | US6120799 For treatment and diagnosisdiseases and abnormalities such as cancer, wound healing, and chronic inflammatory diseases |
| 09/19/2000 | US6120794 Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| 09/19/2000 | US6120793 Transdermal administering |
| 09/19/2000 | US6120789 Non-polymeric sustained release delivery system |
| 09/19/2000 | US6120778 Oil in water emulsion |
| 09/19/2000 | US6120768 Dota-biotin derivatives |
| 09/19/2000 | US6120767 Genetic engineering |
| 09/19/2000 | US6120761 Mixture containing histidine stabilizer |
| 09/19/2000 | US6120758 Preservative system for topically applied products |
| 09/19/2000 | US6120752 Vial equipped with dispensing valve |
| 09/19/2000 | CA2199294C Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions |
| 09/19/2000 | CA2050601C Production in bacteria and yeast of hemoglobin and analogues thereof |
| 09/19/2000 | CA2029673C Process for the production of aqueous mixed micelle solutions |
| 09/14/2000 | WO2000053745A1 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same |
| 09/14/2000 | WO2000053637A1 INCLUSION COMPLEXES OF POLYUNSATURATED FATTY ACIDS AND THEIR DERIVATIVES WITH η-CYCLODEXTRIN |
| 09/14/2000 | WO2000053633A2 Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases |
| 09/14/2000 | WO2000053623A1 Bifunctional molecules for delivery of therapeutics |
| 09/14/2000 | WO2000053578A1 Vitamin d derivatives and process for the preparation thereof |
| 09/14/2000 | WO2000053576A1 Gelling or coagulating agents for liquid organic media |
| 09/14/2000 | WO2000053566A1 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt |
| 09/14/2000 | WO2000053236A2 Methods and compositions for targeted drug delivery |
| 09/14/2000 | WO2000053233A1 Use of protein conformation for the protection and release of chemical compounds |
| 09/14/2000 | WO2000053231A2 Fatty acid-anticancer conjugates and uses thereof |
| 09/14/2000 | WO2000053230A2 Surface modification of lamellar particles |
| 09/14/2000 | WO2000053229A2 Protein conjugates on the basis of lumazine synthase, methods for producing them and the use thereof |
| 09/14/2000 | WO2000053228A2 Use of niaouli essential oil as transdermal permeation enhancer |
| 09/14/2000 | WO2000053227A1 Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors |
| 09/14/2000 | WO2000053226A1 Compositions for promoting percutaneous absorption |
| 09/14/2000 | WO2000053223A1 Apoptosis inducing molecule ii and methods of use |
| 09/14/2000 | WO2000053221A1 Intranasal delivery of pneumococcal polysaccharide vaccines |
| 09/14/2000 | WO2000053213A2 Cyanovirin conjugates, matrix-anchored cyanovirin and anti-cyanovirin antibody, and related compositions and methods of use |
| 09/14/2000 | WO2000053194A1 Remedies for joint diseases |
| 09/14/2000 | WO2000053191A2 Modulation of skeletal muscle precursor cell activation |
| 09/14/2000 | WO2000053184A1 Drug composition for percutaneous absorption |
| 09/14/2000 | WO2000053173A1 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors |
| 09/14/2000 | WO2000053167A2 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
| 09/14/2000 | WO2000053157A1 Improved powdery pharmaceutical compositions for inhalation |
| 09/14/2000 | WO2000037109A3 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions |
| 09/14/2000 | WO2000025812A3 Method for preparing solid phase conjugate vaccines |
| 09/14/2000 | WO2000024893A3 Methods and compositions for the prevention and treatment of anemia |
| 09/14/2000 | WO1999063999A8 H1-histamine receptor antagonists |